T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,749	185 Pages	360iResearch	January, 2024	IRE18450906

Best Price Guarantee
Price	from $4,749
Length	185 Pages
Publisher	360iResearch
Published Date	January, 2024
SKU	IRE18450906

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2024-2030

The T-Cell Therapy Market size was estimated at USD 8.13 billion in 2023 and expected to reach USD 9.85 billion in 2024, at a CAGR 21.23% to reach USD 31.30 billion by 2030.

Global T-Cell Therapy Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the T-Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the T-Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd..

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Modality
Commercialized
Research
Therapy Type
CAR T-cell Therapy
T Cell Receptor-Based
Tumor Infiltrating Lymphocytes-Based
Indication
Hematologic Malignancies
Leukemia

Lymphoma

Myeloma
Solid Tumors
Brain & Central Nervous System

Liver Cancer

Melanoma
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the T-Cell Therapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the T-Cell Therapy Market?
3. What are the technology trends and regulatory frameworks in the T-Cell Therapy Market?
4. What is the market share of the leading vendors in the T-Cell Therapy Market?
5. Which modes and strategic moves are suitable for entering the T-Cell Therapy Market?

Note: PDF & Excel + Online Access - 1 Year

1. Preface: 1.1. Objectives of the Study; 1.2. Market Segmentation & Coverage; 1.3. Years Considered for the Study; 1.4. Currency & Pricing; 1.5. Language; 1.6. Limitations; 1.7. Assumptions; 1.8. Stakeholders
2. Research Methodology: 2.1. Define: Research Objective; 2.2. Determine: Research Design; 2.3. Prepare: Research Instrument; 2.4. Collect: Data Source; 2.5. Analyze: Data Interpretation; 2.6. Formulate: Data Verification; 2.7. Publish: Research Report; 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview: 4.1. Introduction; 4.2. T-Cell Therapy Market, by Region
5. Market Insights: 5.1. Market Dynamics; 5.1.1. Drivers; 5.1.1.1. Increasing approvals along with expanding manufacturing capabilities; 5.1.1.2. Alarming rate of increase in prevalence of cancers; 5.1.1.3. Availability of adequate reimbursements with government awareness; 5.1.2. Restraints; 5.1.2.1. Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits; 5.1.3. Opportunities; 5.1.3.1. Exponential R&D funding for immuno-oncology sector; 5.1.3.2. Expanding adoption of gene and cell therapy; 5.1.4. Challenges; 5.1.4.1. Safety issues and possible side-effects; 5.2. Market Segmentation Analysis; 5.3. Market Trend Analysis; 5.4. Cumulative Impact of High Inflation; 5.5. Porter’s Five Forces Analysis; 5.5.1. Threat of New Entrants; 5.5.2. Threat of Substitutes; 5.5.3. Bargaining Power of Customers; 5.5.4. Bargaining Power of Suppliers; 5.5.5. Industry Rivalry; 5.6. Value Chain & Critical Path Analysis; 5.7. Regulatory Framework
6. T-Cell Therapy Market, by Modality: 6.1. Introduction; 6.2. Commercialized; 6.3. Research
7. T-Cell Therapy Market, by Therapy Type: 7.1. Introduction; 7.2. CAR T-cell Therapy; 7.3. T Cell Receptor-Based; 7.4. Tumor Infiltrating Lymphocytes-Based
8. T-Cell Therapy Market, by Indication: 8.1. Introduction; 8.2. Hematologic Malignancies; 8.3.1. Leukemia; 8.3.2. Lymphoma; 8.3.3. Myeloma; 8.3. Solid Tumors; 8.4.1. Brain & Central Nervous System; 8.4.2. Liver Cancer; 8.4.3. Melanoma
9. Americas T-Cell Therapy Market: 9.1. Introduction; 9.2. Argentina; 9.3. Brazil; 9.4. Canada; 9.5. Mexico; 9.6. United States
10. Asia-Pacific T-Cell Therapy Market: 10.1. Introduction; 10.2. Australia; 10.3. China; 10.4. India; 10.5. Indonesia; 10.6. Japan; 10.7. Malaysia; 10.8. Philippines; 10.9. Singapore; 10.10. South Korea; 10.11. Taiwan; 10.12. Thailand; 10.13. Vietnam
11. Europe, Middle East & Africa T-Cell Therapy Market: 11.1. Introduction; 11.2. Denmark; 11.3. Egypt; 11.4. Finland; 11.5. France; 11.6. Germany; 11.7. Israel; 11.8. Italy; 11.9. Netherlands; 11.10. Nigeria; 11.11. Norway; 11.12. Poland; 11.13. Qatar; 11.14. Russia; 11.15. Saudi Arabia; 11.16. South Africa; 11.17. Spain; 11.18. Sweden; 11.19. Switzerland; 11.20. Turkey; 11.21. United Arab Emirates; 11.22. United Kingdom
12. Competitive Landscape: 12.1. FPNV Positioning Matrix; 12.2. Market Share Analysis, By Key Player; 12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio: 13.1. Key Company Profiles; 13.1.1. AbbVie Inc.; 13.1.2. Adaptimmune Therapeutics PLC; 13.1.3. Amgen Inc.; 13.1.4. Bluebird Bio, Inc.; 13.1.5. Bristol Myers Squibb; 13.1.6. DiaCarta, Inc.; 13.1.7. Fate Therapeutics Inc.; 13.1.8. Gilead Sciences, Inc.; 13.1.9. Merck KGaA; 13.1.10. Novartis AG; 13.1.11. Pfizer Inc.; 13.1.12. Poseida Therapeutics Inc.; 13.1.13. Sorrento Therapeutics, Inc.; 13.1.14. Takara Bio Inc.; 13.1.15. Tessa Therapeutics Pte. Ltd.; 13.2. Key Product Portfolio
14. Appendix: 14.1. Discussion Guide; 14.2. License & Pricing; FIGURE 1. T-CELL THERAPY MARKET RESEARCH PROCESS; FIGURE 2. T-CELL THERAPY MARKET SIZE, 2023 VS 2030; FIGURE 3. T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION); FIGURE 4. T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%); FIGURE 5. T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 6. T-CELL THERAPY MARKET DYNAMICS; FIGURE 7. T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2030 (%); FIGURE 8. T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 9. T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%); FIGURE 10. T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 11. T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%); FIGURE 12. T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 14. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 15. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%); FIGURE 16. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 17. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 18. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 20. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 21. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023; FIGURE 22. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023

T-Cells therapy Market Assessment, By Modality [Research, Commercialized], By Therapy Type [CAR T-cell Therapy, T-Cell Receptor based, Tumor Infiltrating Lymphocytes based], By Indication [Hematologic Malignancies, Solid Tumors, Other], By End-user [Hospitals, Cancer Treatment Centers], By Region, Opportunities and Forecast, 2016-2030F

October, 2023 | Published by: Market Xcel | USD $4,500
United States T-Cells Therapy Market Assessment, By Modality [Research, Commercialized], By Therapy Type [CAR T-Cell Therapy, T-Cell Receptor-based, Tumor-Infiltrating Lymphocytes-based], By Indication [Hematologic Malignancies, Solid Tumors, Others], By End-user [Hospitals, Cancer Treatment Centers], By Region, Opportunities and Forecast, 2016-2030F

October, 2023 | Published by: Market Xcel | USD $3,300
Global T-Cell Therapy Market Size, Trends & Growth Opportunity, By Modality (Research, and Commercialized), By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), By Indication, By End User, By Region and Forecast from 2022-2027.

December, 2022 | Published by: QualiKet Research | USD $3,950
Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

January, 2024 | Published by: The Insight Partners | USD $3,550
T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma)), And Segment Forecasts, 2023 - 2030

February, 2023 | Published by: Grand View Research | USD $5,950
Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

January, 2024 | Published by: The Insight Partners | USD $3,550

PDF E-mail From Publisher:	$4,749
PDF E-mail From Publisher (2-5)Users License:	$5,749
Site License:	$6,749
Global Site License Fulfilled by Publisher:	$8,749

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2024-2030

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2024-2030

Research Assistance

Other tasks

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2024-2030

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2024-2030

Global T-Cell Therapy Market Size, Trends & Growth Opportunity, By Modality (Research, and Commercialized), By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), By Indication, By End User, By Region and Forecast from 2022-2027.

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma)), And Segment Forecasts, 2023 - 2030

Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

Research Assistance

Other tasks